Multiple Sclerosis KOL Insight Interview
Multiple Sclerosis KOL Insight Interview
$599.00
Multiple Sclerosis KOL Insight Interview
Publisher: BioMedTracker
- Description
- Contents
KOL Highlights
- The Receptos RPC1063 data itself is not a surprise; it’s in-line with what we see with Gilenya.(RCPT)
- Unimpressed with daclizumab Phase III DECIDE data. (BIIB)
- Long-term data for Tecfidera shows that people are starting to work out some of the side effect issues. (BIIB)
- Tysabri is a great drug for patients with agressive disease, but the downside of PML risk. If JCV virus index is 0.9 or below – there is a low threshold to start treatment. (BIIB)
- anti-LINGO will likely have mild to modest disease modifying effects in humans. (BIIB)
Contents
Highlights………………………………………………………………………3
RPC1603 RADIANCE trial……………………………………………………4
Daclizumab DECIDE trial…………………………………………………….5
Tecfidera DEFINE, CONFIRM, and ENDORSE long-term follow-up……6
Treatment practices in first and second-line patients……………………..7
Tysabri usage and JCV testing………………………………………………7
anti-CD20 therapies……………………………………………………………8
Myelin desensitization therapies……………………………………………..9
Anti-LINGO and myelin regeneration therapies……………………………10
Tysabri ASCEND trial upcoming data……………………………………….11
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2014 October Dermatology Survey 
Sign up to the